Login to Your Account



FDA Panel Backs Approval of Theravance Antibiotic

By Donna Young


Thursday, November 20, 2008
COLLEGE PARK, Md. - A panel of federal advisers Wednesday supported approval of Theravance Inc.'s injectable antibiotic telavancin, despite the potential for the drug to cause birth defects and kidney problems. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription